Evidence map›Paper›PMID 28357460›Full record

ArticlePsychopharmacology2017

Naltrexone moderates the relationship between cue-induced craving and subjective response to methamphetamine in individuals with methamphetamine use disorder.

Daniel J O Roche, Matthew J Worley, Kelly E Courtney, Spencer Bujarski, Edythe D London, Steven Shoptaw, Lara A Ray

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Psychopharmacology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed.

  1. Bupropion and Naltrexone in Methamphetamine Use Disorder.The New England journal of medicine · 2021
    Trial
  2. Trial
  3. Review
  4. Article
  5. Article
  6. Article
  7. Review
  8. Observational
  9. A Scoping Review on Cue Reactivity in Methamphetamine Use Disorder.International journal of environmental research and public health · 2020
    Article
  10. The role of the opioid system in decision making and cognitive control: A review.Cognitive, affective & behavioral neuroscience · 2019
    Review
  11. Article
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Daniel J O RocheDepartment of Psychology, University of California, Los Angeles, 1285 Franz Hall, Box 951563, Los Angeles, CA, 90095-1563, USA.
Matthew J WorleyDepartment of Psychiatry, University of California, San Diego, San Diego, CA, USA.
Kelly E CourtneyDepartment of Psychiatry, University of California, San Diego, San Diego, CA, USA.
Spencer BujarskiDepartment of Psychology, University of California, Los Angeles, 1285 Franz Hall, Box 951563, Los Angeles, CA, 90095-1563, USA.
Edythe D LondonDepartment of Psychiatry and Biobehavioral Sciences, University of California, Los Angeles, Los Angeles, CA, USA.
Steven ShoptawDepartment of Family Medicine, University of California, Los Angeles, Los Angeles, CA, USA.
Lara A RayDepartment of Psychology, University of California, Los Angeles, 1285 Franz Hall, Box 951563, Los Angeles, CA, 90095-1563, USA. lararay@psych.ucla.edu.

Funding

UCLA Clinical and Translational Science InstituteUL1TR000124 · NCATS · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI DUBINETT, STEVEN M. · 2012 to 2015
$57.0M
UCLA Rapid, Relevant, Rigorous Implementation Science HubP30MH058107 · NIMH · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI RAPHAEL J LANDOVITZ · 1997 to 2026
$53.5M
UCLA CLINICAL AND TRANSLATIONAL SCIENCE INSTITUTEUL1RR033176 · NCRR · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI DUBINETT, STEVEN M. · 2011 to 2011
$15.5M
UCLA Training Program in Translational Neuroscience of Drug Abuse (TNDA)T32DA024635 · NIDA · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI LARA A. RAY, Kate M Wassum · 2008 to 2026
$6.2M
Behavioral economic mechanisms of prescription opioid addiction in chronic painK23DA039348 · NIDA · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI WORLEY, MATTHEW J. · 2016 to 2020
$1.0M
Pharmacogenetics of Natlrexone for Methamphetamine Use DisorderR21DA029831 · NIDA · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI RAY, LARA A. · 2011 to 2013
$478k
Subjective Response and Self-Administration of Alcohol in the Human LabF31AA022569 · NIAAA · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI BUJARSKI, SPENCER · 2014 to 2015
$69k
The Effects of Naltrexone on Neural Responses to Methamphetamine CuesF31DA035604 · NIDA · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI COURTNEY, KELLY ELIZABETH · 2013 to 2014
$66k
NCATS NIH HHS UL1 TR000124NCRR NIH HHS UL1 RR033176NIAAA NIH HHS F31 AA022569NIDA NIH HHS F31 DA035604NIDA NIH HHS K23 DA039348NIDA NIH HHS R21 DA029831NIDA NIH HHS T32 DA024635NIMH NIH HHS P30 MH058107
6 · The paper itself

Abstract

rationaleReductions in cue-induced craving and subjective response to drugs of abuse are commonly used as initial outcome measures when testing novel medications for the treatment of addiction. Yet neither the relationship between these two measures at the individual level nor the moderating effects of pharmacotherapies on this relationship has been examined.

objectiveThis secondary data analysis sought to examine (1) the predictive relationship between cue-induced craving and subsequent acute subjective response to methamphetamine (MA) and (2) whether the opioid-receptor antagonist naltrexone moderated this association in a sample of non-treatment-seeking individuals who met DSM-IV criteria for MA use disorder (abuse or dependence).

methodsParticipants (n = 30) completed two 4-day medication regimens (oral naltrexone 50 mg or placebo, in a randomized, counterbalanced, and double-blind fashion). On day 4 of each medication regimen, participants completed a cue-reactivity paradigm followed by intravenous MA administration. Methamphetamine craving was assessed after the cue-reactivity paradigm, and subjective response to MA was assessed during MA infusion.

resultsCue-induced craving for MA was positively associated with post-infusion subjective MA effects, including positive (i.e., stimulation, good effects, feel drug, high), negative (i.e., anxious and depressed), and craving-related (i.e., want more, would like access to drug, crave) responses. Naltrexone, vs. placebo, significantly reduced the association between cue-induced craving and positive subjective response to MA.

conclusionsThe findings indicate that naltrexone moderates the predictive relationship between cue-induced craving and positive subjective effects of MA, thereby suggesting a behavioral mechanism by which naltrexone may be efficacious in treating MA use disorder.

Indexed as

AnxietyBehavior, AddictiveConditioning, PsychologicalCravingCuesData CollectionDouble-Blind MethodEmotionsHumansMethamphetamineNaltrexoneTime FactorsMethamphetamineNaltrexoneCravingMethamphetamineNaltrexoneSubjective response

Identifiers

PMID28357460
PMCPMC5480611

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.